Ruxolitinib: all 324 studies that test it

Page 2 of 4. Open to participants first (83), then studies with results posted, then the rest; newest registration first within each.

• Study of Ruxolitinib Cream for the Treatment of Discoid Lupus ErythematosusCompletedNCT04908280Phase 2Results posted
• A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)CompletedNCT04896385Phase 2Results posted
• The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic DermatitisCompletedNCT04839380Phase 2Results posted
• Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell CarcinomaTerminatedNCT04807777Phase 2Results posted
• Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe ThrombocytopeniaTerminatedNCT04543279Phase 2Results posted
• Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With VitiligoCompletedNCT04530344Phase 3Results posted
• Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis LipoidicaCompletedNCT04492618Phase 2Results posted
• INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersCompletedNCT04455841Phase 1/2Results posted
• Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa TreatmentTerminatedNCT04414514Phase 2Results posted
• Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)TerminatedNCT04377620Phase 3Results posted
• Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRSCompletedNCT04374149Phase 2Results posted
• Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine StormCompletedNCT04362137Phase 3Results posted
• Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationCompletedNCT04281498Phase 2Results posted
• Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)CompletedNCT04057573Phase 3Results posted
• Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSCompletedNCT04055844Phase 2Results posted
• Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)CompletedNCT04052425Phase 3Results posted
• Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host DiseaseActive, not recruitingNCT03954236Phase 2Results posted
• Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsTerminatedNCT03878199Phase 1/2Results posted
• Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell TransplantCompletedNCT03774082Phase 2Results posted
• LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaCompletedNCT03773107Phase 1/2Results posted
• TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03745651Phase 3Results posted
• Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03745638Phase 3Results posted
• Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 ExpansionActive, not recruitingNCT03722407Phase 2Results posted
• Topical Ruxolitinib Lichen PlanusCompletedNCT03697460Phase 2Results posted
• Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaActive, not recruitingNCT03654768Phase 2Results posted
• Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic GlucocorticoidsCompletedNCT03616184Phase 2Results posted
• Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host DiseaseCompletedNCT03491215Phase 1/2Results posted
• Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.CompletedNCT03427866Phase 2Results posted
• Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT03395340Phase 2Results posted
• A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With MyelofibrosisCompletedNCT03222609Phase 2Results posted
• Ruxolitinib in Operable Head and Neck CancerTerminatedNCT03153982Phase 2Results posted
• A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With MyelofibrosisCompletedNCT03144687Phase 2Results posted
• Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)TerminatedNCT03123588Phase 2Results posted
• VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial CancerActive, not recruitingNCT03120624Phase 1Results posted
• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)CompletedNCT03112603Phase 3Results posted
• A Study of INCB018424 Phosphate Cream in Subjects With VitiligoCompletedNCT03099304Phase 2Results posted
• Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03041636Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic DermatitisCompletedNCT03011892Phase 2Results posted
• Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.CompletedNCT02966353Phase 2Results posted
• A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)CompletedNCT02953678Phase 2Results posted
• Ruxolitinib for Premalignant Breast DiseaseCompletedNCT02928978Phase 2Results posted
• Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell TransplantationCompletedNCT02913261Phase 3Results posted
• Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerCompletedNCT02876302Phase 2Results posted
• Topical Ruxolitinib for the Treatment of VitiligoCompletedNCT02809976Phase 2Results posted
• Long-Term Side Effects of Ruxolitinib in Treating Patients With MyelofibrosisCompletedNCT02784496Phase 2Results posted
• A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisTerminatedNCT02718300Phase 2Results posted
• Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02713386Phase 1/2Results posted
• Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.TerminatedNCT02598297Phase 3Results posted
• A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)TerminatedNCT02553330Phase 2Results posted
• Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected AdultsCompletedNCT02475655Phase 2Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseTerminatedNCT02436135Phase 1Results posted
• Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaTerminatedNCT02420717Phase 2Results posted
• A Pilot Study of Ruxolitinib in Secondary Hemophagocytic SyndromeCompletedNCT02400463Phase 2Results posted
• Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.CompletedNCT02292446Phase 3Results posted
• Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)CompletedNCT02267278Phase 2Results posted
• Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid LeukemiaCompletedNCT02257138Phase 1/2Results posted
• JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT02251821Phase 2Results posted
• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesCompletedNCT02158858Phase 1/2Results posted
• Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibCompletedNCT02155465Phase 1/2Results posted
• A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerTerminatedNCT02120417Phase 2Results posted
• Study of Ruxolitinib in Colorectal Cancer PatientsTerminatedNCT02119676Phase 2Results posted
• A Study of Ruxolitinib in Pancreatic Cancer PatientsTerminatedNCT02119663Phase 3Results posted
• Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerTerminatedNCT02119650Phase 2Results posted
• Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)TerminatedNCT02117479Phase 3Results posted
• Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid LeukemiaCompletedNCT02092324Phase 2Results posted
• A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)TerminatedNCT02091752Phase 2Results posted
• A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) MyelofibrosisCompletedNCT02087059Phase 3Results posted
• Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast CancerCompletedNCT02066532Phase 1/2Results posted
• Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.CompletedNCT02049450Phase 2Results posted
• Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory BrcaCompletedNCT02041429Phase 1/2Results posted
• Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.CompletedNCT02038036Phase 3Results posted
• Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia AreataCompletedNCT01950780Phase 2Results posted
• Ruxolitinib Prior to Transplant in Patients With MyelofibrosisTerminatedNCT01790295Phase 2Results posted
• A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFCompletedNCT01787552Phase 1/2Results posted
• A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of RuxolitinibCompletedNCT01776723Phase 1/2Results posted
• Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With MyelofibrosisCompletedNCT01732445Phase 2Results posted
• Ruxolitinib for Adult T-Cell LeukemiaTerminatedNCT01712659Phase 1/2Results posted
• Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)CompletedNCT01693601Phase 1/2Results posted
• Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief StudyCompletedNCT01632904Phase 3Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• Ruxolitinib in Estrogen Receptor Positive Breast CancerCompletedNCT01594216Phase 2Results posted
• Ruxolitinib in Patients With Breast CancerTerminatedNCT01562873Phase 2Results posted
• Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)CompletedNCT01558739Phase 4Results posted
• INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.CompletedNCT01493414Phase 3Results posted
• Alternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisCompletedNCT01445769Phase 2Results posted
• Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell TransplantCompletedNCT01431209Phase 2Results posted
• Study of Ruxolitinib in Pancreatic Cancer PatientsCompletedNCT01423604Phase 2Results posted
• Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFCompletedNCT01392443Phase 2Results posted
• Ruxolitinib and Lenalidomide for Patients With MyelofibrosisCompletedNCT01375140Phase 2Results posted
• Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)CompletedNCT01348490Phase 2Results posted
• Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsCompletedNCT01340651Phase 2Results posted
• Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)CompletedNCT01317875Phase 1Results posted
• Phase l/II Study of Ruxolitinib for Acute LeukemiaTerminatedNCT01251965Phase 1/2Results posted
• Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)CompletedNCT01243944Phase 3Results posted
• COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialCompletedNCT00952289Phase 3Results posted
• Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II TrialCompletedNCT00934544Phase 3Results posted
• A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque PsoriasisCompletedNCT00820950Phase 2Results posted
• A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque PsoriasisCompletedNCT00778700Phase 2Results posted
• Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT00726232Phase 2Results posted
• INCB018424 in Patients With Advanced Hematologic MalignanciesCompletedNCT00674479Phase 2Results posted

← Ruxolitinib overview